Tuesday, October 27, 2015 3:50:50 PM
Looking at the numbers for next year, we sit at $5.95. That would put us at $148.75 for next year. I think this VRX ordeal could cause a retest of the lows again for biotech. I know I am waiting for that opportunity should we get it. I am a buyer at and below $110. I still see 28 to 30B in long term peak sales for this current pipeline. Right now we have Revlimid, Abraxane, Pomalyst and Otezla to drive earnings out to 2018 and 2019 when we would see Morgesen and Ozanimod reach the market.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM